Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines

Clinical Cancer Research

Volumn 12, Issue 21, 2006, Pages 6547-6556

  Robles, Ana I ^a   Wright, Mollie H ^a   Gandhi, Bheru ^a   Feis, Steven S ^a   Hanigan, Christin L ^a   Wiestner, Adrian ^b   Varticovski, Lyuba ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 (DIMETHYLAMINOETHYLAMINO) 17 DEMETHOXYGELDANAMYCIN; CHECKPOINT KINASE 1; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P53; SB 218078; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; LYMPHOMA CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; LACTAMS, MACROCYCLIC; LYMPHOMA; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33751258936     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1178     Document Type: Article

References (57)

1. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-9.
2. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 2004;3: 997-1007.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253: 49-53.
4. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene 2002;21:6898-907.
5. Schwartz D, Rotter V. p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol 1998;8:325-36.
6. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996;6:12-8.
7. Zhou BB, Anderson HJ, Roberge M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther 2003;2:516-22.
8. 2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-9.
9. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
10. 2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. Anticancer Res 2001;21:23-8.
11. Senderowicz AM. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 2004;16:670-8.
12. Garber K. New checkpoint blockers begin human trials. J Natl Cancer Inst 2005;97:1026-8.
13. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15:419-24.
14. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
15. Isaacs JS. Heat-shock protein 90 inhibitors in anti-neoplastic therapy: is it all wrapped up? Expert Opin Investig Drugs 2005;14:569-89.
16. Blagosklonny MV, Fojo T, Bhalla KN, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001;15:1537-43.
17. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001;61:1799-804.
18. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99.
19. Bisht KS, Bradbury CM, Mattson D, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003;63:8984-95.
20. Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004; 15:377-87.
21. Hollingshead M, Alley M, Burger AM, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005;56:115-25.
22. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
23. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93
24. Hwang K, Scripture CD, Gutierrez M, Kummar S, Figg WD, Sparreboom A. Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino- 17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005.
25. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23: 4152-61.
26. Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 2001;61: 6660-4.
27. Coiffier B. Current strategies for the treatment of diffuse large B cell lymphoma. Curr Opin Hematol 2005; 12:259-65.
28. Kerbauy FR, Colleoni GW, Saad ST, et al. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature. Leuk Lymphoma 2004;45:2071-8.
29. Drexler HG, Fombonne S, Matsuo Y, Hu ZB, Hamaguchi H, Uphoff CC. p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization? Leukemia 2000; 14:198-206.
30. Liber HL, Yandell DW, Little JB. A comparison of mutation induction at the tk and hprt loci in human lymphoblastoid cells: quantitative differences are due to an additional class of mutations at the autosomal tk locus. Mutat Res 1989;216:9-17.
31. Bhatia K, Goldschmidts W, Gutierrez M, Gaidano G, Dalla-Favera R, Magrath I. Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEB J 1993;7:951-6.
32. Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000; 60:566-72.
33. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
34. Xu B, Kim S, Kastan MB. Involvement of Brca1 in S-phase and G (2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001;21:3445-50.
35. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005;56: 126-37.
36. Munster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001;61:2945-52.
37. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004;279: 53272-81.
38. Artender SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7.
39. Flatten K, Dai NT, Vroman BT, et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J Biol Chem 2005;280:14349-55.
40. Mesa RA, Loegering D, Powell HL, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005;106: 318-27.
41. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner.
42. See: E.A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res, 7:2155-2158, 2001.
43. Clin Cancer Res 2001;7:2228-36.
44. Liao ZY, Zhang SH, Zhen YS. Synergistic effects of geldanamycin and antitumor drugs. Yao Xue Xue Bao 2001;36:569-75.
45. 2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 2004;10:8077-84.
46. Hawkins LM, Jayanthan AA, Narendran A. Effects of 17-allylamino-17- demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatr Res 2005;57:430-7.
47. Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-lnhibition of P-glycoprotein function by 17-AAG. Leukemia 2005; 19:1198-206.
48. Rahmani M, Yu C, Dai Y, et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003;63:8420-7.
49. Demidenko ZN, Vivo C, Halicka HD, et al. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Differ 2006;13:1434-41.
50. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005;65:10536-44.
51. Kim HR, Kang HS, Kim HD. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 1999;48:429-33.
52. Haupt Y, Rubles AI, Prives C, Rotter V. Deconstruction of p53 functions and regulation. Oncogene 2002; 21:8223-31.
53. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992; 89:7491-5.
54. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005;331:868-80.
55. Nagata Y Anan T, Yoshida T, et al. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association. Oncogene 1999;18:6037-49.
56. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 2003;100:13791-6.
57. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon ad enocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res 2003;63:3241-6.